Please assess the completion status of the following clinical trial:

Trial Title: Targeted Chemo-elimination (TCE) of Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
OxTREC reference: 1017-13~Inclusion Criteria:~* Age ≥6 months, male or female,~* Written informed consent (by parent/guardian in case of children)~Exclusion Criteria:~* Pregnant women will not receive primaquine (urine pregnancy tests will be performed on women of appropriate age groups before drug administration at each TCE round)~* History of allergy or known contraindication to artemisinins, piperaquine or PQ~* Those who are, in the opinion of the study clinician, ill at the time of drug administration~OxTREC reference: 1015-13~Inclusion Criteria~* Age ≥6 months, male or female,~* Written informed consent (by legally acceptable representative in case of children)~* Healthy at the time of the survey or drug administration~* Not pregnant~Exclusion Criteria~* Significant non-compliance with study requirements~* Loss to follow up~* Suspected severe adverse events~* Severe illness~OxTREC reference: 23-15~Part 1. qPCR survey for identification of potential TMT villages;~Inclusion criteria:~* Males and females 18 and above~* Written informed consent~Exclusion criteria:~* Pregnant women in their first trimester~* Presence of any acute severe illness at the time of survey~Part 2. TMT villages will be given directly observed therapy (DOT) with DP for 3 days and PQ (0.25 mg/kg) will be given on day 1~Inclusion criteria for TMT~* Age ≥one year, male and female,~* Willing to provide consent for those 18 years and above. For children 10-18 years old, parents/guardians must provide consent, and the children must provide assent. For children below 10 years old, the parents/guardians must provide consent.~Exclusion criteria for TMT~* History of allergy or known contraindication to artemisinins, piperaquine or PQ.~* Refusal of treatment.~* Pregnant women in their 1st trimester.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- malaria elimination using DP and low-dose primaquine (Type: EXPERIMENTAL): Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
- Control villages (Type: NO_INTERVENTION): Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete